107 related articles for article (PubMed ID: 22728751)
1. Monotherapy with atazanavir as a simplification strategy: results from an observational study.
Cossarini F; Salpietro S; Galli L; Gianotti N; Nozza S; Spagnuolo V; Hasson H; Bossolasco S; Lazzarin A; Tambussi G; Castagna A
J Acquir Immune Defic Syndr; 2012 Jul; 60(3):e101-3. PubMed ID: 22728751
[No Abstract] [Full Text] [Related]
2. Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice.
Santos JR; Moltó J; Llibre JM; Pérez N; Capitán ; Miranda C; Clotet B
HIV Clin Trials; 2009; 10(3):129-34. PubMed ID: 19632951
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patients.
Bonora S; Calcagno A; Vigano O; Bigliano P; Marinaro L; Colella E; Orofino G; Trentini L; Tettoni MC; D'Avolio A; Mercadante S; Galli M; Di Perri G; Rusconi S
Curr HIV Res; 2014; 12(5):339-46. PubMed ID: 25106410
[TBL] [Abstract][Full Text] [Related]
4. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results.
Murphy RL; Sanne I; Cahn P; Phanuphak P; Percival L; Kelleher T; Giordano M
AIDS; 2003 Dec; 17(18):2603-14. PubMed ID: 14685054
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
[TBL] [Abstract][Full Text] [Related]
6. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial.
Haas DW; Zala C; Schrader S; Piliero P; Jaeger H; Nunes D; Thiry A; Schnittman S; Sension M;
AIDS; 2003 Jun; 17(9):1339-49. PubMed ID: 12799555
[TBL] [Abstract][Full Text] [Related]
7. Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients.
Khanlou H; Bhatti L; Farthing C
J Acquir Immune Defic Syndr; 2006 Jan; 41(1):124-5. PubMed ID: 16340485
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients.
Horberg M; Klein D; Hurley L; Silverberg M; Towner W; Antoniskis D; Kovach D; Mogyoros M; Blake W; Dobrinich R; Dodge W
HIV Clin Trials; 2008; 9(6):367-74. PubMed ID: 19203902
[TBL] [Abstract][Full Text] [Related]
9. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
[TBL] [Abstract][Full Text] [Related]
10. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Atazanavir in treatment-experienced patients.
Sax PE
AIDS Clin Care; 2003 Sep; 15(9):78. PubMed ID: 14666914
[TBL] [Abstract][Full Text] [Related]
11. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
[TBL] [Abstract][Full Text] [Related]
12. Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.
Cordery DV; Hesse K; Amin J; Cooper DA
Antivir Ther; 2010; 15(7):1035-8. PubMed ID: 21041919
[TBL] [Abstract][Full Text] [Related]
13. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy.
Karlström O; Josephson F; Sönnerborg A
J Acquir Immune Defic Syndr; 2007 Apr; 44(4):417-22. PubMed ID: 17159658
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of atazanavir in patients with end-stage liver disease.
Guaraldi G; Cocchi S; Motta A; Ciaffi S; Codeluppi M; Bonora S; Di Benedetto F; Masetti M; Floridia M; Baroncelli S; Pinetti D; Bertolini A; Gerunda GE; Esposito R
Infection; 2009 Jun; 37(3):250-5. PubMed ID: 19471855
[TBL] [Abstract][Full Text] [Related]
15. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.
Squires K; Lazzarin A; Gatell JM; Powderly WG; Pokrovskiy V; Delfraissy JF; Jemsek J; Rivero A; Rozenbaum W; Schrader S; Sension M; Vibhagool A; Thiry A; Giordano M
J Acquir Immune Defic Syndr; 2004 Aug; 36(5):1011-9. PubMed ID: 15247553
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.
Malan DR; Krantz E; David N; Wirtz V; Hammond J; McGrath D;
J Acquir Immune Defic Syndr; 2008 Feb; 47(2):161-7. PubMed ID: 17971713
[TBL] [Abstract][Full Text] [Related]
17. Simplified maintenance therapy with abacavir/lamivudine and atazanavir after discontinuation of ritonavir.
Elion R; Berger D; Richmond G; Sension M; Dejesus E; Cimoch P; St Clair M; Yau L; Ha B;
HIV Clin Trials; 2010; 11(3):170-3. PubMed ID: 20736153
[No Abstract] [Full Text] [Related]
18. Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.
Tremblay C; Trottier B; Rachlis A; Baril JG; Loutfy M; Lalonde R; Sampalis JS; Boulerice F
HIV Clin Trials; 2011; 12(3):151-60. PubMed ID: 21684855
[TBL] [Abstract][Full Text] [Related]
19. Unexpected improvement of sexual dysfunction during atazanavir therapy.
Bernal E; Masiá M; Padilla S; Gutiérrez F
AIDS; 2005 Sep; 19(13):1440-1. PubMed ID: 16103782
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
